Paper Details

  1. Home
  2. Paper Details

Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study.

Author: CrookJuanita, DahrougeSimone, MaloneShawn, PerryGad, SegalRoanne

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Intermittent androgen suppression therapy (IAS) showed potential for reducing side effects in patients with prostate cancer, including recovery of hemoglobin levels, sexual function, and absence of weight gain.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To assess the feasibility and tolerability of intermittent androgen suppression therapy (IAS) in prostate cancer. PATIENTS AND METHODS: Patients with recurrent or metastic prostate cancer received cyclical periods of treatment with leuprolide acetate and nilutamide for 8 months, and rest...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1464-410X.2005.05676.x

データ提供：米国国立医学図書館（NLM）

Intermittent Androgen Suppression: A New Approach for Prostate Cancer

Prostate cancer is a common disease that can be as challenging to manage as navigating a vast and unforgiving desert. This study examines the feasibility and tolerability of intermittent androgen suppression (IAS) therapy for prostate cancer. The researchers conducted a phase II trial, comparing IAS to continuous androgen suppression (CAS) therapy. They found that IAS was feasible and well-tolerated, with fewer side effects compared to CAS. Patients experienced periods of testosterone recovery during the rest periods, allowing for a reduction in side effects.

Finding a Balance in Prostate Cancer Treatment

This research provides valuable insights into the potential benefits of IAS therapy for prostate cancer. The study's findings suggest that IAS may offer a more manageable treatment approach, balancing effectiveness with reduced side effects.

Improved Quality of Life for Prostate Cancer Patients

The study's results suggest that IAS therapy may improve the quality of life for prostate cancer patients by reducing side effects and allowing for periods of testosterone recovery. This could lead to better overall well-being and a more positive experience for patients undergoing treatment.

Dr. Camel's Conclusion

This study offers valuable insights into the potential benefits of intermittent androgen suppression for prostate cancer patients. The study's findings suggest that IAS may offer a more manageable treatment approach, balancing effectiveness with reduced side effects, potentially improving the quality of life for patients. As researchers, we continue to explore new treatment options for prostate cancer, seeking solutions that improve patient outcomes and enhance their overall well-being.

Date :
  1. Date Completed 2005-09-28
  2. Date Revised 2014-11-20
Further Info :

Pubmed ID

16104902

DOI: Digital Object Identifier

10.1111/j.1464-410X.2005.05676.x

Related Literature

Article Analysis
・Side Effects of nilutamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.